Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study

被引：0
|
作者：
Jun Guo
Yiran Huang
Xu Zhang
Fangjian Zhou
Yinghao Sun
Shukui Qin
Zhangqun Ye
Hui Wang
Annette Jappe
Patrick Straub
Nicoletta Pirotta
Sven Gogov
机构：
[1] Peking University Cancer Hospital and Institute,
[2] Shanghai Renji Hospital,undefined
[3] The General Hospital of PLA,undefined
[4] Sun Yat-sen University Cancer Center,undefined
[5] Shanghai Changhai Hospital,undefined
[6] Nanjing Bayi Hospital,undefined
[7] Wuhan Tongji Hospital,undefined
[8] Beijing Novartis Pharma Company,undefined
[9] Ltd.,undefined
[10] Novartis Pharma AG,undefined
[11] Novartis Pharma AG,undefined
[12] Novartis Pharma AG,undefined
[13] Novartis Pharma AG,undefined
来源：
BMC Cancer | / 13卷
关键词：
Asian; Everolimus; mTOR inhibitor; Renal cell cancer; Sunitinib; Sorafenib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Activity of Single-Agent Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
    Turnbull, James D.
    Cobert, Julien
    Jaffe, Tracy
    Harrison, Michael R.
    George, Daniel J.
    Armstrong, Andrew J.
    CLINICAL GENITOURINARY CANCER, 2013, 11 (01) : 45 - 50
  • [22] Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor
    Park, Inkeun
    Lee, Jae-Lyun
    Ahn, Jin-Hee
    Lee, Dae-Ho
    Lee, Kyoo-Hyung
    You, Dalsan
    Jeong, In Gab
    Song, Cheryn
    Hong, Bumsik
    Hong, Jun Hyuk
    Ahn, Hanjong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (05) : 1025 - 1035
  • [23] Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI
    Park, Kwonoh
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Seongjoon
    Ahn, Yongcheol
    Ahn, Jin-Hee
    Ahn, Shin
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    MEDICAL ONCOLOGY, 2012, 29 (05) : 3291 - 3297
  • [24] Correlation of Degree of Hypothyroidism With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors
    Bailey, Erin B.
    Tantravahi, Srinivas K.
    Poole, Austin
    Agarwal, Archana M.
    Straubhar, Alli M.
    Batten, Julia A.
    Patel, Shiven B.
    Wells, Chesley E.
    Stenehjem, David D.
    Agarwal, Neeraj
    CLINICAL GENITOURINARY CANCER, 2015, 13 (03) : E131 - E137
  • [25] Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI
    Kwonoh Park
    Jae-Lyun Lee
    Inkeun Park
    Seongjoon Park
    Yongcheol Ahn
    Jin-Hee Ahn
    Shin Ahn
    Cheryn Song
    Jun Hyuk Hong
    Choung-Soo Kim
    Hanjong Ahn
    Medical Oncology, 2012, 29 : 3291 - 3297
  • [26] Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors
    Pal, Sumanta K.
    Li, Sierra M.
    Wu, Xiwei
    Qin, Hanjun
    Kortylewski, Marcin
    Hsu, Joann
    Carmichael, Courtney
    Frankel, Paul
    CLINICAL CANCER RESEARCH, 2015, 21 (23) : 5286 - 5293
  • [27] Efficacy and safety of anti-vascular endothelial growth factor therapies in older patients for first line treatment of metastatic renal cell carcinoma
    Dupuis, Hugo Georges Arthur
    Chebbi, Ala
    Surlemont, Louis
    Rigal, Olivier
    Di Fiore, Frederic
    Pfister, Christian
    Nouhaud, Francois-Xavier
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2021, 10 (06) : 2418 - 2426
  • [28] A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies
    McKay, Rana R.
    De Velasco, Guillermo
    Werner, Lillian
    Bellmunt, Joaquim
    Harshman, Lauren
    Sweeney, Christopher
    Rosenberg, Jonathan E.
    Hirsch, Michelle
    Signoretti, Sabina
    Van Allen, Eliezer M.
    Walsh, Meghara
    Vaishampayan, Ulka
    McDermott, David F.
    Choueiri, Toni K.
    CANCER, 2016, 122 (15) : 2389 - 2398
  • [29] High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor
    Pouessel, Damien
    Culine, Stephane
    EUROPEAN UROLOGY, 2008, 53 (02) : 376 - 381
  • [30] Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World
    Gebbia, Vittorio
    Girlando, Andrea
    Di Grazia, Alfio
    Fazio, Ivan
    Borsellino, NicolO
    Piazza, Dario
    Serretta, Vincenzo
    Pergolizzi, Stefano
    Pontoriero, Antonio
    Firenze, Alberto
    Valerio, Maria Rosaria
    ANTICANCER RESEARCH, 2020, 40 (12) : 7037 - 7043
12345